The company is conducting trials with its experimental drug pegozafermin in patients with severe scarring of the liver. In patients who were not taking GLP-1s, 45% of those who were on Akero's ...

The firm's confidence in the biopharmaceutical company's prospects is tied to the progress of its Phase 3 ENTRUST study of pegozafermin, a treatment for severe hypertriglyceridemia (SHTG). The study ...

The firm’s confidence in the biopharmaceutical company’s prospects is tied to the progress of its Phase 3 ENTRUST study of pegozafermin, a treatment for severe hypertriglyceridemia (SHTG). The study ...

The firm's confidence in the biopharmaceutical company's prospects is tied to the progress of its Phase 3 ENTRUST study of pegozafermin, a treatment for severe hypertriglyceridemia (SHTG).

该公司对这家生物制药公司前景的信心与其pegozafermin治疗严重高甘油三酯血症(SHTG)的III期ENTRUST研究进展密切相关。该研究已成功完成患者招募，预计将在2025年下半年公布顶线数据。 ENTRUST试验是一项全球III期试验，旨在评估pegozafermin在最多360名SHTG患者中的疗效。

(Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ...

Additionally, the ongoing Phase 3 ENLIGHTEN program in NASH, which investigates pegozafermin in both non-cirrhotic and cirrhotic conditions, has garnered significant interest from key opinion ...